Sodium stibogluconate

Structural formula
	possible structure, see section Structure
General
Surname	Sodium stibogluconate
other names	Sodium stibogluconate
Molecular formula	C 12 H 35 Na 3 O 26 Sb 2
External identifiers / databases
EC number	642-992-3
ECHA InfoCard	100.170.909
PubChem	70682647
ChemSpider	28525872
DrugBank	DB05630
Wikidata	Q2757844
Drug information
ATC code	P01 CB02 ; Q P51AB02 ;
properties
Molar mass	907.9 g · mol -1
safety instructions
	Please note the exemption from the labeling requirement for drugs, medical devices, cosmetics, food and animal feed
GHS hazard labeling ; no classification available
	As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Sodium stibogluconate is a drug that is used in the treatment of leishmaniasis . It was added to the World Health Organization 's Essential Medicines List in 1988 .

Chemical properties

structure

The structure of the present antimony (V) complex could not be elucidated for a long time. Investigations with current analytical methods suggest that sodium stibogluconate is present as a mixture of different oligomeric structures, the composition in the solid state being different from that in solution.

Medical aspects

Sodium stibogluconate is used in the treatment of various forms of leishmaniasis , namely visceral leishmaniasis, mucocutaneous, diffuse cutaneous, disseminated and disfiguring cutaneous leishmaniasis. Usually, a dosage that differs according to type is selected over a period of approx. 30 days, which can also be combined with other preparations such as allopurinol . However, the effectiveness of this combination is controversial.

Trade names

Pentostam ( GlaxoSmithKline )
Lenocta

Web links

Entry on sodium stibogluconate at Vetpharm

literature

Franz von Bruchhausen (eds.), Siegfried Ebel, Eberhard Hackenthal and Ulrike Holzgrabe: Hager's Handbook of Pharmaceutical Practice: Volume 5: Substances L – Z , 5th edition, Springer-Verlag, Berlin Heidelberg, 1999, ISBN 978-3-642 -63569-4 ; ISBN 978-3-642-58388-9 (eBook); doi : 10.1007 / 978-3-642-58388-9 .

Individual evidence

↑ This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.
Jump up ↑ Frézard F, Demicheli C, Ribeiro PR: Pentavalent Antimonials: New Perspectives for Old Drugs . (pdf) In: Molecules . 14, No. 7, 2009, pp. 2317-2336. doi : 10.3390 / molecules14072317 . PMID 19633606 .
↑ A. Llanos-Cuentas, J. Echevarría, M. Cruz, A. La Rosa, P. Campos, M. Campos, E. Franke, J. Berman, F. Modabber, J. Marr: Efficacy of sodium stibogluconate alone and in combination with allopurinol for treatment of mucocutaneous leishmaniasis. In: Clinical Infectious Diseases . Volume 25, Number 3, September 1997, pp. 677-684, PMID 9314461 .

[NV-1] This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.

[2] Jump up ↑ Frézard F, Demicheli C, Ribeiro PR: Pentavalent Antimonials: New Perspectives for Old Drugs . (pdf) In: Molecules . 14, No. 7, 2009, pp. 2317-2336. doi : 10.3390 / molecules14072317 . PMID 19633606 .

[3] A. Llanos-Cuentas, J. Echevarría, M. Cruz, A. La Rosa, P. Campos, M. Campos, E. Franke, J. Berman, F. Modabber, J. Marr: Efficacy of sodium stibogluconate alone and in combination with allopurinol for treatment of mucocutaneous leishmaniasis. In: Clinical Infectious Diseases . Volume 25, Number 3, September 1997, pp. 677-684, PMID 9314461 .